DK1468092T3 - Pim-3-kinase som et mål for type 2-diabetes mellitus - Google Patents

Pim-3-kinase som et mål for type 2-diabetes mellitus

Info

Publication number
DK1468092T3
DK1468092T3 DK03701530.2T DK03701530T DK1468092T3 DK 1468092 T3 DK1468092 T3 DK 1468092T3 DK 03701530 T DK03701530 T DK 03701530T DK 1468092 T3 DK1468092 T3 DK 1468092T3
Authority
DK
Denmark
Prior art keywords
pim
type
diabetes mellitus
kinase
target
Prior art date
Application number
DK03701530.2T
Other languages
English (en)
Inventor
Guenter Mueller
Marcus Korn
Georg Tschank
Rudolf Schneider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1468092T3 publication Critical patent/DK1468092T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03701530.2T 2002-01-19 2003-01-20 Pim-3-kinase som et mål for type 2-diabetes mellitus DK1468092T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001401 2002-01-19
PCT/EP2003/000492 WO2003060130A2 (en) 2002-01-19 2003-01-20 Pim-3 kinase as a target for type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
DK1468092T3 true DK1468092T3 (da) 2012-05-07

Family

ID=8185311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03701530.2T DK1468092T3 (da) 2002-01-19 2003-01-20 Pim-3-kinase som et mål for type 2-diabetes mellitus

Country Status (14)

Country Link
EP (1) EP1468092B1 (da)
JP (1) JP4272533B2 (da)
KR (2) KR101205194B1 (da)
CN (1) CN100467601C (da)
AT (1) ATE541040T1 (da)
BR (1) BR0306984A (da)
CA (2) CA2473566C (da)
DK (1) DK1468092T3 (da)
IL (1) IL194074A (da)
MX (1) MXPA04006906A (da)
NO (1) NO333253B1 (da)
RU (1) RU2316598C2 (da)
WO (1) WO2003060130A2 (da)
ZA (1) ZA200404997B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555323A1 (en) * 2003-08-11 2005-02-17 Kureha Corporation Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide
US20220235343A1 (en) * 2019-06-27 2022-07-28 Industrial Cooperation Foundation Chonbuk National University Novel adp-ribosyl cyclase and inhibitor thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0911391A3 (en) * 1997-10-24 2000-01-19 Smithkline Beecham Corporation A clone HWHHJ20
US6143540A (en) * 1999-01-26 2000-11-07 Millennium Pharmaceuticals, Inc. Molecules of the HKID-1-related protein family and uses thereof
CN1328134A (zh) * 2001-04-13 2001-12-26 复旦大学 一种蛋白激酶编码序列,其编码的多肽、制法及用途
DE10123055A1 (de) * 2001-05-11 2003-03-20 Gruenenthal Gmbh Screeningverfahren mit PIM1-Kinase oder PIM3-Kinase

Also Published As

Publication number Publication date
IL194074A (en) 2011-08-31
CN1620505A (zh) 2005-05-25
BR0306984A (pt) 2004-12-14
KR101158326B1 (ko) 2012-06-28
CA2680946C (en) 2013-03-12
ZA200404997B (en) 2006-05-31
CA2680946A1 (en) 2003-07-24
KR20040075940A (ko) 2004-08-30
EP1468092B1 (en) 2012-01-11
WO2003060130A2 (en) 2003-07-24
JP2005514068A (ja) 2005-05-19
RU2316598C2 (ru) 2008-02-10
RU2004125291A (ru) 2005-04-20
NO333253B1 (no) 2013-04-22
MXPA04006906A (es) 2004-12-06
NO20043459L (no) 2004-10-07
CA2473566A1 (en) 2003-07-24
KR101205194B1 (ko) 2012-11-27
WO2003060130A3 (en) 2004-01-15
KR20110011753A (ko) 2011-02-08
ATE541040T1 (de) 2012-01-15
JP4272533B2 (ja) 2009-06-03
CN100467601C (zh) 2009-03-11
EP1468092A2 (en) 2004-10-20
AU2003202579A1 (en) 2003-07-30
CA2473566C (en) 2012-05-01

Similar Documents

Publication Publication Date Title
BRPI0519241A2 (pt) agonistas, composiÇÕes, mÉtodos e usos de glp-1
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
EA200501715A1 (ru) Замещённые аминокарбоновые кислоты в качестве ингибиторов протеинтирозинфосфатазы-1в
BRPI0516126A (pt) produtos farmacêuticos de polipeptìdeos intestinais vasoativos
BR0114310A (pt) Derivados do glicopiranosiloxibenzilbenzeno e composições medicinais contendo os mesmos
BR9814276A (pt) Antìgenos de superfìcie
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
ATE447858T1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
DK1673475T3 (da) Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
BRPI0406680A (pt) Métodos para selecionar um animal para ter propriedades desejadas genotìpicas ou fenotìpicas em potencial, para modular a trascrição de mrna de um gene igf2 em uma célula ou organismo provido com referido gene e para identificar um composto, composto, composição farmacêutica, e, uso de um composto
NO20020470D0 (no) Polymorfier i det humane MDR-1-genet og deres anvendelse i diagnostisk og terapeutiske anvendelser
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
DK1468092T3 (da) Pim-3-kinase som et mål for type 2-diabetes mellitus
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
BR0015170A (pt) Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
BR9814433A (pt) "beta-lipotropina e usos da mesma"
TW200500376A (en) Novel adenosine analogues and their use as pharmaceutical agents